Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEASURE 5: Secukinumab in Ankylosing Spondylitis
NCT02896127Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Secukinumab 150 mg with Placebo -> Secukinumab (2 arms). Primary endpoint: Assessment of SpondyloArthritis International Society 20 Response at 16 weeks. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02896127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896127.